Based on our analysis CDX2 expression could be immunohistochemically tested only in patients with poorly differentiated CRC and MLH1/PMS2 heterodimer deficiency resulting in even less expensive immunohistochemical analysis. This evidence concerns the gene PMS2 and colorectal carcinoma.